Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies

Shares of Adaptimmune have skyrocketed since the opening bell on Jan. 13. The stock closed up 200% Monday after the company announced positive results with its SPEAR-T cancer program and has continued to rise this morning after it struck a deal with Astellas Pharma.